Production of cytokines after lipopolysaccharide stimulation of murine spleen cells during lymphoma development in AKR mice.
Injection of syngeneic lymphoma cells in AKR mice, resulted in an important increase of splenic natural killer (NK) activity in the early days following the graft. Modifications of the production of different types of cytokine: interferon, interleukins 1 and 2, tumor necrosis factor (IFN, IL-1, IL-2, TNF), involved in the regulation of NK activity, were investigated in short-term cultures of total, adherent and non-adherent fractionated spleen cells, using lipopolysaccharide as the triggering or amplifying agent. Upon stimulation with lipopolysaccharide, splenocytes from lymphoma-grafted mice released a large amount of interferon as compared to controls with a maximum level 1 day after the graft. Equal amounts of IFN-gamma and IFN-alpha/beta were detected. Treatment of spleen cells prior to culture with anti-(asialo-GM1) or anti-(Thy-1.1) antibodies reduced interferon production by 80% and 50% respectively. This finding indicates that (a) the IFN-gamma is produced by Thy-1-positive cells and (b) the production of IFN-gamma by these cells is at least partially under the control of asialo-GM1-positive cells. We also showed that non-adherent fractionated spleen cells from lymphoma-grafted mice produced IL-1 and IL-2. IL-1 was released by asialo-GM1-positive cells and IL-2 by Thy-1-positive cells. Adherent cells released only IL-1. In contrast, total cells released smaller amounts of IL-1 and IL-2, suggesting a reciprocal inhibition between subpopulations of non-adherent and adherent cells. A high level of TNF production by adherent cells was observed only 4 days after the graft. These results indicate that graft of lymphoma cells entails important modifications of spleen cell populations releasing different types of cytokines implicated in NK activation.
Vaillier
D
D
INSERM U.117, Unité de Radiobiologie Expérimentale et de Cancérologie, Bordeaux, France.
Daculsi
R
R
Legrand
E
E
Guillemain
B
B
D000818:Animals; D000906:Antibodies / Q000502:physiology; D000954:Antigens, Surface / Q000276:immunology; D001685:Biological Factors / Q000096:biosynthesis*; D002448:Cell Adhesion; D002469:Cell Separation; D002474:Cell-Free System; D016207:Cytokines; D003602:Cytotoxicity, Immunologic; D005260:Female; D005677:G(M1) Ganglioside; D006028:Glycosphingolipids / Q000276:immunology; D007372:Interferons / Q000096:biosynthesis; D007375:Interleukin-1 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000276:immunology; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000378:metabolism*; D008223:Lymphoma / Q000209:etiology / Q000378:metabolism*; D008297:Male; D051379:Mice; D008806:Mice, Inbred AKR; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D013154:Spleen; D018800:Thy-1 Antigens; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000906:Antibodies; D000954:Antigens, Surface; D001685:Biological Factors; D016207:Cytokines; D006028:Glycosphingolipids; D007375:Interleukin-1; D007376:Interleukin-2; D008070:Lipopolysaccharides; D018800:Thy-1 Antigens; D014409:Tumor Necrosis Factor-alpha; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside; D007372:Interferons